GOSSGossamer Bio, Inc.

Nasdaq gossamerbio.com


$ 0.92 $ -0.05 (-5.38 %)    

Friday, 28-Jun-2024 15:59:39 EDT
QQQ $ 479.98 $ -2.50 (-0.52 %)
DIA $ 391.11 $ -0.43 (-0.11 %)
SPY $ 544.70 $ -2.15 (-0.39 %)
TLT $ 91.77 $ -1.74 (-1.86 %)
GLD $ 215.03 $ 0.02 (0.01 %)
$ 0.9009
$ 0.95
$ 0.91 x 100
$ 0.00 x 0
$ 0.90 - $ 0.95
$ 0.45 - $ 1.88
1,309,904
na
203.36M
$ 1.25
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 03-05-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-17-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-09-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 03-03-2022 12-31-2021 10-K
11 11-08-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-26-2021 12-31-2020 10-K
15 11-10-2020 09-30-2020 10-Q
16 08-11-2020 06-30-2020 10-Q
17 05-12-2020 03-31-2020 10-Q
18 03-24-2020 12-31-2019 10-K
19 11-12-2019 09-30-2019 10-Q
20 08-08-2019 06-30-2019 10-Q
21 05-14-2019 03-31-2019 10-Q
22 03-22-2019 12-31-2018 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 gossamer-bios-clean-safety-profile-differentiates-it-from-merck-analyst-says

Oppenheimer initiated coverage on Gossamer Bio, highlighting seralutinib's clean long-term safety profile for pulmonary art...

 oppenheimer-initiates-coverage-on-gossamer-bio-with-outperform-rating-announces-price-target-of-9

Oppenheimer analyst Andreas Argyrides initiates coverage on Gossamer Bio (NASDAQ:GOSS) with a Outperform rating and announce...

 goldman-sachs-maintains-buy-on-gossamer-bio-maintains-8-price-target

Goldman Sachs analyst Paul Choi maintains Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $8 price target.

 hc-wainwright--co-reiterates-buy-on-gossamer-bio-maintains-10-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $10 price ta...

 gossamer-bio-provides-updated-seralutinib-torrey-open-label-extension-data-at-the-american-thoracic-society-2024-international-conference-which-takes-place-may-17-22

Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization o...

 wedbush-reiterates-outperform-on-gossamer-bio-maintains-4-price-target

Wedbush analyst Laura Chico reiterates Gossamer Bio (NASDAQ:GOSS) with a Outperform and maintains $4 price target.

 gossamer-bio-q1-eps-019-misses-018-estimate

Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.18...

 gossamer-bio-collaborates-with-italian-drugmaker-chiesi-to-advance-lung-health-solutions-worldwide

Gossamer Bio partners with Chiesi Farmaceutici to develop and market seralutinib globally, targeting pulmonary arterial hyperte...

 hc-wainwright--co-reiterates-buy-on-gossamer-bio-maintains-10-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $10 price ta...

 gossamer-bio-secures-160m-partnership-with-chiesi-group-to-accelerate-development-of-pulmonary-hypertension-treatment-486m-potential-for-seralutinib-collaboration

Gossamer Bio, Inc. ("Gossamer") (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development an...